CD8A and neoplasm: The YAP1 pathway inhibitor verteporfin reduced tumor burden in mice and increased the proportion of TAM M1 cells, while also enhancing the percentage of activated CD8+ T cells and decreasing the proportion of stem-like malignant cells.